Home LiteratureArticle Details
PMID: 18847302 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Personalized vaccines: the emerging field of vaccinomics.

Expert opinion on biological therapy ·Vol. 8 ·No. 11 ·2008-11-00 ·Pages 1659-67

Poland GA, Ovsyannikova IG, Jacobson RM

Abstract

The next 'golden age' in vaccinology will be ushered in by the new science of vaccinomics. In turn, this will inform and allow the development of personalized vaccines, based on our increasing understanding of immune response phenotype: genotype information. Rapid advances in developing such data are already occurring for hepatitis B, influenza, measles, mumps, rubella, anthrax and smallpox vaccines. In addition, newly available data suggest that some vaccine-related adverse events may also be genetically determined and, therefore, predictable. This paper reviews the basis and logic of personalized vaccines, and describes recent advances in the field.

MeSH Terms
Allergy and Immunology Female Genetic Markers Genetic Predisposition to Disease Genotype HLA Antigens/chemistry Humans Immune System Immunization Schedule Male Phenotype Polymorphism, Genetic Sex Factors Vaccination Vaccines/chemistry
Chemicals
Genetic Markers HLA Antigens Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Poland Gregory A
Mayo Clinic College of Medicine, Mayo Vaccine Research Group, Program in TranslationalImmunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota 55905, USA. poland.gregory@mayo.edu
Ovsyannikova Inna G
Jacobson Robert M
References (72)
72 references, click to expand
  1. The effects of hormones on sex differences in infection: from genes to behavior.
    Neurosci Biobehav Rev. 2000 Aug;24(6):627-38 PMID: 10940438
  2. The extent and analysis of cytokine and cytokine receptor gene polymorphism.
    Transpl Immunol. 2002 Aug;10(2-3):143-6 PMID: 12216945
  3. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?
    Trends Pharmacol Sci. 2003 Jun;24(6):284-9 PMID: 12823954
  4. Differential antibody responses to rubella virus infection in males and females.
    J Infect Dis. 1992 Dec;166(6):1258-65 PMID: 1431244
  5. The immunogenetics of smallpox vaccination.
    J Infect Dis. 2007 Jul 15;196(2):212-9 PMID: 17570108
  6. Therapeutics and toxicology.
    Curr Opin Pediatr. 1998 Apr;10(2):201-2 PMID: 9608900
  7. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.
    Clin Pharmacol Ther. 2007 Dec;82(6):653-64 PMID: 17971814
  8. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.
    JAMA. 2003 Jun 25;289(24):3283-9 PMID: 12824210
  9. Mass spectrometry and peptide-based vaccine development.
    Clin Pharmacol Ther. 2007 Dec;82(6):644-52 PMID: 17971823
  10. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination.
    Vaccine. 2004 May 7;22(15-16):1914-20 PMID: 15121303
  11. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response.
    Am J Hum Genet. 1998 Feb;62(2):215-20 PMID: 9463343
  12. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results.
    Vaccine. 2008 Mar 25;26(14):1731-6 PMID: 18325643
  13. Vaccines: correlates of vaccine-induced immunity.
    Clin Infect Dis. 2008 Aug 1;47(3):401-9 PMID: 18558875
  14. Vaccine safety--vaccine benefits: science and the public's perception.
    Nat Rev Immunol. 2001 Nov;1(2):160-5 PMID: 11905824
  15. Genetic epidemiology of single-nucleotide polymorphisms.
    Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15173-7 PMID: 10611357
  16. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles.
    J Immunol. 2000 Jul 15;165(2):1123-37 PMID: 10878392
  17. Sex differences in the humoral antibody response to live measles vaccine in young adults.
    Int J Epidemiol. 1994 Oct;23(5):1078-81 PMID: 7860159
  18. Cytokine expression patterns associated with systemic adverse events following smallpox immunization.
    J Infect Dis. 2006 Aug 15;194(4):444-53 PMID: 16845627
  19. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.
    Vaccine. 2003 Mar 7;21(11-12):1174-9 PMID: 12559795
  20. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T-cell determinant within a native antigen: relevance to disease susceptibility and vaccination.
    Scand J Immunol. 2007 Feb;65(2):158-65 PMID: 17257220
  21. Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling.
    J Transl Med. 2003 Nov 18;1(1):8 PMID: 14624696
  22. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40 PMID: 17585291
  23. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.
    Curr Opin Immunol. 2003 Aug;15(4):461-70 PMID: 12900280
  24. HLA, Gm, and Km polymorphisms and immunity to infectious diseases in South Amerinds.
    Exp Clin Immunogenet. 1995;12(3):206-16 PMID: 8534507
  25. The HLA system. Second of two parts.
    N Engl J Med. 2000 Sep 14;343(11):782-6 PMID: 10984567
  26. Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination.
    J Infect Dis. 2007 Jun 15;195(12):1799-807 PMID: 17492596
  27. The HLA system. First of two parts.
    N Engl J Med. 2000 Sep 7;343(10):702-9 PMID: 10974135
  28. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    J Infect Dis. 2006 Mar 1;193(5):655-63 PMID: 16453260
  29. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
    J Virol. 2007 Aug;81(16):8774-83 PMID: 17553867
  30. Response to hepatitis B vaccine: multiple HLA genes are involved.
    Tissue Antigens. 1998 Jun;51(6):593-604 PMID: 9694351
  31. Genetic predisposition for adverse events after vaccination.
    J Infect Dis. 2007 Jul 15;196(2):176-7 PMID: 17570102
  32. Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents.
    Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1626-32 PMID: 17684137
  33. Declining population immunity to mumps among Israeli military recruits.
    Vaccine. 2006 Sep 11;24(37-39):6300-3 PMID: 16844272
  34. Implications of the Human Genome Project for medical science.
    JAMA. 2001 Feb 7;285(5):540-4 PMID: 11176855
  35. Immunology. The shape of things to come.
    Science. 2007 Jun 15;316(5831):1574-6 PMID: 17569850
  36. The X-files in immunity: sex-based differences predispose immune responses.
    Nat Rev Immunol. 2008 Sep;8(9):737-44 PMID: 18728636
  37. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better?
    Lancet Infect Dis. 2006 Oct;6(10):653-63 PMID: 17008174
  38. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination.
    Hepatology. 2004 Apr;39(4):978-88 PMID: 15057902
  39. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine.
    Pediatrics. 2008 May;121(5):e1091-9 PMID: 18450852
  40. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children.
    N Engl J Med. 1990 Nov 15;323(20):1387-92 PMID: 2233905
  41. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms.
    Nature. 2001 Feb 15;409(6822):928-33 PMID: 11237013
  42. Myopericarditis following smallpox vaccination.
    Am J Epidemiol. 2004 Oct 1;160(7):642-51 PMID: 15383408
  43. A measles epidemic threshold in a highly vaccinated population.
    PLoS Med. 2005 Nov;2(11):e316 PMID: 16218769
  44. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children.
    J Infect Dis. 1992 Jun;165 Suppl 1:S144-51 PMID: 1588150
  45. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program.
    Vaccine. 2005 Mar 18;23(17-18):2078-81 PMID: 15755574
  46. Identification of an association between HLA class II alleles and low antibody levels after measles immunization.
    Vaccine. 2001 Nov 12;20(3-4):430-8 PMID: 11672906
  47. Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: novel epitopes identified from chronic carriers.
    Virus Res. 1997 Aug;50(2):185-94 PMID: 9282783
  48. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels.
    J Infect Dis. 2004 Apr 15;189(8):1401-10 PMID: 15073677
  49. Genetic basis for adverse events after smallpox vaccination.
    J Infect Dis. 2008 Jul 1;198(1):16-22 PMID: 18454680
  50. Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.
    J Virol. 2004 Jan;78(1):42-51 PMID: 14671086
  51. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Pediatr Infect Dis J. 1999 Jan;18(1):42-8 PMID: 9951979
  52. The Future of Smallpox Vaccination: is MVA the key?
    Med Immunol. 2005 Mar 01;4(1):2 PMID: 15740619
  53. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.
    Pediatrics. 2003 Oct;112(4):958-63 PMID: 14523192
  54. Pharmacology, vaccinomics, and the second golden age of vaccinology.
    Clin Pharmacol Ther. 2007 Dec;82(6):623-6 PMID: 17998905
  55. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk.
    Gynecol Oncol. 2003 Mar;88(3):326-32 PMID: 12648582
  56. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design.
    Vaccine. 2007 Apr 20;25(16):3090-100 PMID: 17280755
  57. Pros and cons of genetic association studies in hepatitis B.
    Hepatology. 2004 Aug;40(2):284-6 PMID: 15368431
  58. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.
    Hum Immunol. 2004 Dec;65(12):1506-15 PMID: 15603879
  59. Class II HLA alleles and hepatitis B virus persistence in African Americans.
    J Infect Dis. 1999 Apr;179(4):1004-6 PMID: 10068598
  60. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.
    JAMA. 2004 Jul 21;292(3):351-7 PMID: 15265850
  61. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors.
    J Allergy Clin Immunol. 2007 Sep;120(3):666-72 PMID: 17560639
  62. Immunogenicity of peptides of measles virus origin and influence of adjuvants.
    Vaccine. 2006 Jan 12;24(2):185-94 PMID: 16122851
  63. Balanced polymorphism selected by genetic versus infectious human disease.
    Annu Rev Genomics Hum Genet. 2002;3:263-92 PMID: 12142357
  64. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
    J Infect Dis. 2005 Feb 15;191(4):515-9 PMID: 15655774
  65. The genetic basis for variation in antibody response to vaccines.
    Curr Opin Pediatr. 1998 Apr;10(2):208-15 PMID: 9608902
  66. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
    Science. 2007 Jun 15;316(5831):1628-32 PMID: 17569868
  67. Learning to appreciate our differences.
    J Infect Dis. 2008 Jul 1;198(1):4-5 PMID: 18454681
  68. Response to immunization with Haemophilus influenzae type b polysaccharide-pertussis vaccine and risk of Haemophilus meningitis in children with the Km(1) immunoglobulin allotype.
    J Clin Invest. 1984 Nov;74(5):1708-14 PMID: 6334101
  69. Vaccine immunogenetics: bedside to bench to population.
    Vaccine. 2008 Nov 18;26(49):6183-8 PMID: 18598732
  70. Ab and T cell epitopes of influenza A virus, knowledge and opportunities.
    Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):246-51 PMID: 17200302
  71. Variation in HLA class I antigen-processing genes and susceptibility to human papillomavirus type 16-associated cervical cancer.
    J Infect Dis. 2008 Feb 1;197(3):371-81 PMID: 18248301
  72. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry.
    J Proteome Res. 2005 Nov-Dec;4(6):2243-9 PMID: 16335972
Article Info
Journal
Expert opinion on biological therapy
Abbr.
Expert Opin Biol Ther
ISSN
1744-7682
DOI
10.1517/14712598.8.11.1659
Email
poland.gregory@mayo.edu
Published
2008-11-00
Pages
1659-67
Language
English
Region
England
NLM ID
101125414
PMCID
PMC2831634
Subset
IM
Grants
NIAID NIH HHS · R01 AI033144 · United States
NIAID NIH HHS · N01 AI040065 · United States
NIAID NIH HHS · R01 AI048793-08 · United States
NIAID NIH HHS · N01AI40065 · United States
NIAID NIH HHS · R01 AI048793 · United States
NIAID NIH HHS · R01 AI033144-14A2 · United States
NIAID NIH HHS · R37 AI048793 · United States
NIAID NIH HHS · AI 48793 · United States
NIAID NIH HHS · AI 33144 · United States
External Links
PubMed source DOI: 10.1517/14712598.8.11.1659 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2